A Company Built for Patients.

We are a team of scientists, physicians and entrepreneurs determined to unlock the potential of cannabinoid-based medicines using precision technologies to deliver relief for patients with unmet medical needs.

Gregory F. Wesner

Chief Executive Officer

Mr. Wesner is a leading intellectual property attorney and corporate growth strategist with decades of experience in pharmaceutical and life sciences companies. As counsel and advisor to corporate leadership he has designed and implemented IP-driven strategies to power growth, financing, mergers and acquisitions, and public offerings.

In his law firm leadership roles he has recruited and managed diverse technical and legal teams in high-stakes patent litigation, IP portfolio development, and global risk management. He has been recognized as a SuperLawyer every year since 2007 and is listed as one of the Best Lawyers in America in the field of intellectual property. He is a frequent speaker and serves as a media consultant on intellectual property issues including those affecting the global cannabinoid industry. His thought leadership on cannabinoid IP has appeared in publications such as the World Trademark Review and the Cannabis Law Journal.

Receptor’s dry powder inhalation technology, Receptor AIR™, exclusively licensed from MannKind Corporation, resulted from Mr. Wesner’s experience as intellectual property counsel to MannKind. Mr. Wesner managed an exhaustive analysis of worldwide pulmonary drug delivery technologies and became convinced MannKind’s inhalation system is the only one capable of safely, reliably and precisely delivering cannabinoid-based drugs rapidly to the bloodstream. That insight led to Receptor and MannKind’s global partnership.

Orrin Devinsky, M.D.

Chief Medical Officer

Dr. Devinsky is the Director of the New York University (NYU) Comprehensive Epilepsy Center and the Saint Barnabas Institute of Neurology and Neurosurgery. He is also a Professor of Neurology, Neurosurgery, and Psychiatry at NYU Langone School of Medicine. Dr. Devinsky specializes in epilepsy and behavioral neurology.

He serves as a reviewer for more than 30 journals and is a member of the Scientific Advisory Board for many disease organizations. He has published more than 500 articles and book chapters and has led multiple antiepileptic clinical trials. Dr. Devinsky has current research support from NINDS, NIMH, NIBIB, DoD, MURI, National Science Foundation and Simmons Foundation.

In the field of cannabinoid research, Dr. Devinsky served as a principal investigator for the development of GW Pharmaceuticals' Epidiolex (cannabidiol, or CBD) for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS), a rare and severe form of childhood-onset epilepsy.

Andrea Leone-Bay, PH.D.

Chief Scientific Officer

Dr. Leone-Bay is the former Vice-President and head of pharmaceutical development for MannKind Corporation. Dr. Leone-Bay is an internationally recognized authority on dry powder and oral drug delivery technologies. She brings unparalleled pharmaceutical formulation expertise with 48 publications in peer-reviewed journals and 93 issued U.S. patents.

She also has decades of drug development expertise, and has managed corporate divisions dedicated to research, development and commercialization of regulated drug products and drug-device combinations.

Traci A. Carman

Chief Financial Officer

Ms. Carman is an experienced finance and operations executive whose strategic insight and expertise led to the financial growth and scalable operations of a number of corporations, non-profits, and startups across a range of industries. Ms. Carman’s track record includes securing several successful funding rounds, pre-IPO financial reporting, and structuring and closing multiple critical financings for startup companies. Ms. Carman has led and scaled all aspects of finance, accounting, tax, FP&A, treasury, risk management, debt and equity financing, and M&A.